How Long from Kick-off to Certificate: Backward Timeline Planning

1. Key takeaways

For a Class B, Class C or Class D device, the project from kick-off to certificate should be planned on 10 to 15 months. For a Class A device, plan on 4 to 6 months. The overall timeline has four segments: the holder entity and LTO at 1 to 3 months, document preparation and authentication at 2 to 4 months, technical review at 6 to 9 months or about 30 working days on the Abridged pathway, and a deficiency buffer of 1 to 3 months.

• The four segments are not equally controllable: three sit with the applicant and one sits with the regulator.
• Backward scheduling from the target launch month exposes time gaps that forward scheduling hides.
• The LTO, the CSDT and the LOA authentication can run in parallel, and doing so saves months compared with a serial plan.
• Where an ASEAN approval exists, the Abridged pathway compresses the review segment and the overall project from 10 to 15 months to 6 to 9 months.
• The Apostille step depends on external scheduling and should be the first action, not the last.

2. Legal basis

Planning rests on the authorisation framework in AO No. 2018-0002 of 26 January 2018, which sets CMDR review at 180 days from acceptance, and on FC No. 2022-008 of 27 September 2022, which sets a 30 working day target for products already approved by an ASEAN NRA. The FDA Citizens Charter lists 20 working days for a medical device manufacturer LTO. Certificates run for 5 years with renewal within 90 days before expiry. Processing conduct is also subject to RA No. 11032 of 2018. Authentication follows the notarisation plus Apostille route, the Hague Convention between China and the Philippines having taken effect on 7 November 2023.

3. Expert insights

Backward scheduling suits the Philippines better than forward scheduling. Forward scheduling starts today and works step by step towards submission, and it systematically underestimates the front-end steps. Backward scheduling starts from the target launch month and subtracts, which forces the gaps into view. GRZAN’s standard method is: take the target month, subtract one month for launch preparation, subtract 6 to 9 months for review, subtract 1 to 3 months for the LTO, subtract 2 to 4 months for documentation and authentication, and then hold 1 to 3 months of buffer. What remains is the start date, and it is usually earlier than the client expected.

Only one of the four segments sits outside company control. The LTO segment, the documentation segment and the deficiency response segment are all controlled by the applicant; only the technical review segment is controlled by the regulator. That means roughly three quarters of the timeline is within the company’s own reach. In practice, a great deal of project energy goes into chasing the FDA, which is the wrong direction. The effective move is to compress the three applicant segments to their minimum and to make the submission pass on the first attempt. A plan that shows 10 to 15 months with the buffer visible is more useful to management than a plan that shows the 180-day statutory figure and then slips quietly, because the first plan can be managed and the second can only be explained.

Parallel execution saves 3 to 4 months. The serial approach runs the LTO first, then prepares the documents, then completes notarisation and authentication, then submits. The parallel approach starts the LTO and the CSDT drafting at the same time, and runs the LOA notarisation and Apostille alongside document preparation. GRZAN’s project management defaults to the parallel model, particularly for the Apostille step, because the external bodies involved set their own schedules and the applicant cannot accelerate them once the file reaches the front of a queue it joined late.

The Abridged pathway delivers the largest single compression. Where the product has already been approved in an ASEAN member state against the CSDT, the review segment falls from 180 days to about 30 working days, and the overall project can move from 10 to 15 months down to 6 to 9 months. That is the core value of securing an ASEAN reference market first: it does not just save one review, it installs an accelerator for every subsequent ASEAN market in the portfolio.

4. Practical recommendations

• Build the project plan by backward scheduling and lock three milestones. The LTO approval date, the submission date and the certificate date should be fixed in the plan and reported against, rather than left as derived dates.
• Run the three prerequisite workstreams fully in parallel. LTO processing, CSDT drafting and LOA notarisation with Apostille should start in the same week, with a single owner for the interface between them.
• Move the Apostille step to the front. External scheduling is not controllable, so the step with the least control should have the earliest start.
• Secure an ASEAN reference market early. Where an approval in another ASEAN market already exists on the CSDT basis, the Philippine file can use the fast track, and the planning assumption changes accordingly.
• Open a 5-year expiry ledger and a renewal reminder on the day the certificate issues. The project does not end at approval; the next deadline is already known.

5. Verification checklist

• □ Target launch month agreed with the commercial plan.
• □ Backward-scheduled plan includes all four segments: LTO, documentation, review and deficiency buffer.
• □ Three prerequisite workstreams shown as parallel in the project plan.
• □ Apostille initiated at the earliest possible point and its progress tracked.
• □ Abridged eligibility self-check completed: ASEAN NRA approval and non-IVD status.
• □ Post-approval ledger opened: 5-year expiry date and the 90-day renewal window.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com